{"filing":{"accession_number":"0001213900-26-102371","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"ea0306375-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026102371/ea0306375-6k_clearmind.htm"},"events":[{"id":34481,"run_id":31728,"accession_number":"0001213900-26-102371","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA), expanding Clearmind's intellectual property portfolio in psychedelic-derived therapeutics. While the disclosure is operational in nature (patent publication and IP strategy), it represents a material milestone for a clinical-stage biotech company whose competitive position depends significantly on proprietary intellectual property and patent protection. The announcement explicitly notes this comes \"at a significant time\" as regulatory interest in these compounds grows, and the company's IP portfolio now consists of nineteen patent families with 32 granted patents—a key asset for valuation and competitive positioning.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38212,"accession_number":"0001213900-26-102371","item_number":"EX-99.1","item_title":"ea030637501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA), expanding Clearmind's intellectual property portfolio in psychedelic-derived therapeutics. While the disclosure is operational in nature (patent publication and IP strategy), it represents a material milestone for a clinical-stage biotech company whose competitive position depends significantly on proprietary intellectual property and patent protection. The announcement explicitly notes this comes \"at a significant time\" as regulatory interest in these compounds grows, and the company's IP portfolio now consists of nineteen patent families with 32 granted patents—a key asset for valuation and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:53.365692+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38212,"accession_number":"0001213900-26-102371","item_number":"EX-99.1","item_title":"ea030637501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA), expanding Clearmind's intellectual property portfolio in psychedelic-derived therapeutics. While the disclosure is operational in nature (patent publication and IP strategy), it represents a material milestone for a clinical-stage biotech company whose competitive position depends significantly on proprietary intellectual property and patent protection. The announcement explicitly notes this comes \"at a significant time\" as regulatory interest in these compounds grows, and the company's IP portfolio now consists of nineteen patent families with 32 granted patents—a key asset for valuation and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:53.365692+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-23"}]}